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Abstract
Advances in donor matching and immunosuppressive therapies have decreased the prevalence of acute rejection
of cardiac grafts; however, chronic rejection remains a significant obstacle for long-term allograft survival. While
initiating elements of anti-allograft immune responses have been identified, the linkage between these factors
and the ultimate development of cardiac fibrosis is not well understood. Tissue fibrosis resembles an exaggerated
wound healing response, in which extracellular matrix (ECM) molecules are central. One such ECM molecule is an
alternatively spliced isoform of the ubiquitous glycoprotein fibronectin (FN), termed extra domain A-containing
cellular fibronectin (EDA cFN). EDA cFN is instrumental in fibrogenesis; thus, we hypothesized that it might
also regulate fibrotic remodelling associated with chronic rejection. We compared the development of acute
and chronic cardiac allograft rejection in EDA cFN-deficient (EDA−/−) and wild-type (WT) mice. While EDA−/−
mice developed acute cardiac rejection in a manner indistinguishable from WT controls, cardiac allografts in
EDA−/− mice were protected from fibrosis associated with chronic rejection. Decreased fibrosis was not associated
with differences in cardiomyocyte hypertrophy or intra-graft expression of pro-fibrotic mediators. Further, we
examined expression of EDA cFN and total FN by whole splenocytes under conditions promoting various T-helper
lineages. Conditions supporting regulatory T-cell (Treg) development were characterized by greatest production
of total FN and EDA cFN, though EDA cFN to total FN ratios were highest in Th1 cultures. These findings
indicate that recipient-derived EDA cFN is dispensable for acute allograft rejection responses but that it promotes
the development of fibrosis associated with chronic rejection. Further, conditions favouring the development of
regulatory T cells, widely considered graft-protective, may drive production of ECM molecules which enhance
deleterious remodelling responses. Thus, EDA cFN may be a therapeutic target for ameliorating fibrosis associated
with chronic cardiac allograft rejection.
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Introduction
Cardiac transplantation is an important therapeutic
option for patients with end-stage cardiac dysfunction
due to infiltrative disease, ischaemia, or non-ischaemic
cardiomyopathy. While improvements in donor match-
ing and immunosuppressive regimens have greatly
decreased the prevalence of acute allograft rejection,
they have had much less of an impact on chronic
rejection, which remains a leading cause of long-term
patient morbidity and mortality. Chronic cardiac allo-
graft rejection is characterized by vascular remodelling
and occlusion [cardiac allograft vasculopathy (CAV)],
myocardial hypertrophy, and excessive extracellular
matrix (ECM) deposition leading to interstitial fibrosis,
all of which contribute to progressive graft dysfunction
[1–3].
Recipient immune responses against donor graft anti-
gens are believed to play a key role in chronic rejection
and there is significant potential for interplay between
immune cells and ECM molecules [4–6]. The robust
mononuclear cell infiltrate associated with unmodified
acute rejection response is characterized by a domi-
nant elaboration of Th1 cytokines, especially interferon
(IFN)-γ [7,8]. In contrast, chronic transplant rejection
is thought to involve a sub-acute inflammatory process
that over time gives way to a chronic fibroproliferative
response, ultimately resulting in allograft fibrosis and
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functional insufficiency [9–11]. Fibrotic remodelling in
chronic rejection is associated with expression of TGF-
β, which in the setting of cardiac transplantation can
both dampen inflammation [12,13] and promote ECM
production [14,15]. Thus, while TGF-β is important
in chronic rejection, its relationship to co-mediators of
cardiac fibrosis is not well understood.
Chronic rejection resembles exaggerated wound
healing responses, which are by nature driven by ECM
molecules. The ubiquitously expressed ECM glyco-
protein fibronectin (FN) circulates in soluble form in
plasma (plasma FN or pFN), but also constitutes a
major fraction of the cell-derived poorly soluble or
insoluble FN (cellular FN or cFN) fibrils in fibrotic tis-
sues [16–18]. The distinction between pFN and cFN
rests largely on the products of FN pre-mRNA alterna-
tive splicing. Specifically, cFN includes one or both of
the alternatively spliced domains [termed extra domain
A (EDA) and extra domain B (EDB)], whereas pFN
lacks both domains (reviewed in ref 19). With respect
to tissue fibrosis, EDA-containing cFN (EDA cFN)
is better studied, having unique functions in immune
signalling and activation, as well as myofibroblast dif-
ferentiation [16,20,21].
Interestingly, studies have implicated a role for
EDA cFN in both acute and chronic rejection of car-
diac allografts [22–24]. Early observations associated
EDA cFN expression with graft-infiltrating leukocytes,
particularly macrophages [22]. More recent studies
have demonstrated intra-graft expression of EDA cFN
within lesions of CAV and interstitial fibrosis [23,25].
Given these associations between EDA cFN and
chronic cardiac allograft rejection, as well as the known
role of EDA cFN in promoting fibrosis, we sought to
define the role of EDA cFN in chronic cardiac allograft
rejection using a vascularized heterotopic mouse model
to compare acute and chronic rejection in EDA cFN-
deficient (EDA−/−) and wild-type (WT) recipients.
Materials and methods
Mice
Female WT C57BL/6 (H-2b) and BALB/c (H-2d)
mice were purchased from Jackson Laboratories (Bar
Harbor, ME, USA). All animals were kept under micro-
isolator conditions as reviewed and approved by the
University of Michigan’s Committee on the Use and
Care of Animals. Female EDA−/− mice on a C57BL/6
background have been described previously [26].
Culture media
Cells were cultured in RPMI 1640 supplemented with
2% FCS, 1 mM sodium pyruvate, 100 U/ml peni-
cillin, 100 µg/ml streptomycin, 1.6 mM L-glutamine,
10 mM HEPES buffer (Invitrogen, Carlsbad, CA,
USA), 0.27 mM L-asparagine, 1.4 mM L-arginine
HCl, 14 µM folic acid, and 50 µM 2-ME (Sigma-
Aldrich, St Louis, MO, USA).
Blood analysis
Peripheral blood was harvested by direct cardiac punc-
ture from 4- to 6-week-old euthanized mice into EDTA-
containing tubes. Whole blood was analysed for white
cell counts and differentials on a Technicon H1 blood
analyzer (Siemens Diagnostics, Deerfield, IL, USA)
with veterinary software and mouse parameters.
3H-thymidine proliferation assay
WT and EDA−/− splenocytes (1 × 106 per ml) were
harvested and cultured in a 96-well plate for 72 h in
the presence or absence of concanavalin A (Con A)
(1 µg/ml). Cells were pulsed with 3H-thymidine for the
final 18 h of culture. Cultures were then harvested onto
fibre mats and radioactive counts per minute (cpm)
were assessed using a scintillation counter.
Immunohistochemistry
Immunohistochemistry was performed as previously
described [27]. Excised hearts were embedded in
paraffin, sectioned, and stained with H&E or trichrome.
A Nikon Eclipse 50i microscope was used to visualize
and photograph sections.
Differential counts of graft infiltrating cells (GICs)
Portions of at least three transplanted hearts were
pooled and minced before digestion with 1 mg/ml col-
lagenase A (Roche Diagnostics, Penzberg, Germany)
for 30 min at 37 ◦C. After tissue debris had settled,
suspended GICs were harvested. RBCs were lysed
by hypotonic shock and GICs were passed through
a 30 µm nylon mesh. Cytocentrifuged GICs were
Wright-stained for differential enumeration.
ELISPOT assay
Capture and detection antibody pairs (BD Biosciences,
San Jose, CA, USA) were as follows: IFN-γ (R4-
6A2, XMG1.2), IL-4 (11B11, BVD6-24G2), and
IL-17 (TC11-18H10, TC11-8H4.1). Polyvinylidene
difluoride-backed microtitre plates (Millipore, Biller-
ica, MA, USA) were coated with unlabelled mAb and
blocked with 1% BSA in PBS. Irradiated (1000 rad)
BALB/c splenocytes (4 × 105) and 1 × 106 recipient
splenocytes were added to each well for 24 h. After
washing, biotinylated detection mAbs were added to
the plates. Plates were washed and a 1 : 1000 dilution
of anti-biotin alkaline phosphatase conjugate (Vector
Laboratories, Burlingame, CA, USA) was added to
IFN-γ and IL-17 plates, and a 1 : 2000 dilution of HRP-
conjugated streptavidin (Dako, Carpinteria, CA, USA)
was added to IL-4 plates. Plates were washed and
spots were visualized by addition of NBT (Bio-Rad,
Hercules, CA, USA)/3-bromo-4-chloro-indolyl phos-
phate (Sigma-Aldrich) to IFN-γ and IL-17 plates, or
3-amino-9-ethylcarbazole (Pierce, Rockford, IL, USA)
to IL-4 plates. Colour development continued until
spots were visible and was stopped by adding H2O.
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Plates were dried and spots were quantified with an
Immunospot Series 1 ELISPOT analyzer (Cellular
Technology Ltd, Shaker Heights, OH, USA).
Heterotopic cardiac transplantation
Female C57BL/6 (H-2b) and BALB/c (H-2d) mice were
purchased from Jackson Labs. EDA−/− mice were bred
and housed at the University of Michigan, and experi-
mental procedures were approved by the Animal Care
and Use Committees of our institution. Animals were
housed in specific pathogen-free rooms with a 12-h
day/night cycle and had ad libitum access to water
and chow. Heterotopic cardiac transplantation was per-
formed as previously described [28]. Briefly, the aorta
and pulmonary artery of the donor BALB/c heart were
anastomosed end-to-side to the recipient’s abdominal
aorta and inferior vena cava, respectively. Upon perfu-
sion with the recipient’s blood, the transplanted heart
resumes contraction. Graft function was monitored by
abdominal palpation.
In vivo mAb therapy
Anti-CD4 (hybridoma GK1.5) was obtained from
American Type Culture Collection, (Manassas, VA,
USA) and prepared by Bio X Cell (West Lebanon, NH,
USA). Allograft recipients were transiently depleted
of CD4+ cells by i.p. injection of 1 mg of anti-CD4
mAb on the day prior to, the day of, and 7 days post-
transplant [14,15,29].
Morphometric analysis of cardiac graft fibrosis
and hypertrophy
Graft fibrosis was quantified by morphometric analysis
of Masson’s trichrome-stained sections using iPLab
software (Scanalytics Inc, Fairfax, VA, USA). Mean
fibrotic area was calculated from 10–12 areas per
heart section analysed at 200× magnification [14].
To quantify cardiomyocyte area as a measure of
hypertrophy, digital outlines were drawn around at
least 80 cardiomyocytes from views of H&E-stained
sections at 200× magnification [29]. Areas within
outlines were quantified using NIH Image J software
(NIH) to measure cardiomyocyte cell size. A minimum
of six hearts were analysed per group for both analysis
techniques.
Splenocyte Th cultures
WT splenocytes were harvested and cultured at a
density of 1 × 106 per ml with 2% anti-CD3 (YCD3-
1) supernatant for 72 h. Cultures promoting specific Th
lineages were supplemented with the following: Th1:
10 units/ml rIL-2, 10 µg/ml anti-IL-4 (11B11), and
1 ng/ml IL-12; Th2: 10 units/ml rIL-2, 100 ng/ml IL-
4, and 10 µg/ml anti-IFN-γ (R46A2); Th17: 5 ng/ml
recombinant TGF-β and 25 ng/ml rIL-6; Treg: 10
units/ml rIL-2, 10 ng/ml recombinant TGF-β.
Western blotting
Western blot analysis was performed under reducing
conditions from whole-cell lysates prepared in cold
RIPA buffer as described previously [27]. Densitometry
of visualized bands was performed using Image J
software (NIH).
Quantitative real-time PCR
Graft RNA was isolated by homogenizing tissues in
TRIzol reagent (Invitrogen) according to the manufac-
turer’s protocol. Five micrograms of total RNA was
reverse-transcribed using Oligo dT, dNTPs, MMLV-
RT (Invitrogen), and RNAsin (Promega, Madison, WI,
USA) in PCR buffer (Roche, Indianapolis, IN, USA).
Levels of the various transcripts were determined by
quantitative real-time PCR using BioRad SYBR master
mix in a Rotor Gene thermocycler. Expression levels
were determined relative to GAPDH using the Rotor
Gene relative quantitation utility.
RNA from splenocyte cultures was obtained by re-
suspending culture pellets in Trizol reagent. Reverse
transcription was performed with the Applied Biosys-
tems High Capacity Reverse Transcription Kit and
transcript levels were determined using Taq-Man
SYBR master mix in an Applied Biosystems 7300
thermocycler (Applied Biosystems, Foster City, CA,
USA). Expression levels were determined relative
to GAPDH using 2−Ct normalization. Primers for
collagen I, CTGF, IL-6, and IL-17 transcripts were




Murine EDA cFN was detected in serum by coating 96-
well EIA plates (Costar, Lowell, MA, USA) with 3E2
mouse monoclonal anti-EDA FN antibody (1.4 µg/ml;
Sigma) in 0.05 M carbonate–bicarbonate buffer, pH
9.6 (Sigma). Wells were then blocked with 5% BSA in
PBS and serum samples were added in triplicate. Serum
EDA cFN was detected with H-300 rabbit polyclonal
fibronectin antibody (1.4 µg/ml; Santa Cruz Biotech-
nology) in dilution buffer (PBS, 0.05% Tween 20,
1% BSA) followed by HRP-conjugated goat anti-rabbit
IgG secondary antibody (1 : 500; Fisher Scientific) in
dilution buffer. Colour development was with Sigma
Fast OPD tablets (Sigma) in deionized water. Devel-
opment was terminated by the addition of an equal
volume of 0.5 M sulphuric acid. Plates were read at
490 nm and serum values determined by interpolating
against a standard curve. Using purified murine plasma
fibronectin, we confirmed the specificity of the ELISA
for only EDA cFN (data not shown).
Statistical analyses
Statistical analyses were performed using GraphPad
Prism 5.01 (GraphPad Software, La Jolla, CA, USA).
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Figure 1. EDA−/− mice have normal numbers of circulating leukocytes and proliferative capacity. (A) White blood cell counts from whole
blood obtained from WT (n = 11) and EDA−/− (n = 12) mice, analysed as described in the Materials and methods section. (B) Proliferative
responses of WT and EDA−/− splenocytes cultured in the presence or absence of 1 µg/ml concanavalin A (Con A) for 72 h measured by
3H-thymidine incorporation.
Differences between groups were evaluated using Stu-
dent’s t-test. Data were considered significant at p <
0.05.
Results
EDA−/− mice display normal anti-graft immune
responses
Fibronectin is involved in T-cell development and
activation [30,31], and the EDA domain of fibronectin
is believed to stimulate TLR4 (either directly or
indirectly) to promote the production of inflammatory
mediators [21,32]. Thus, we first sought to determine
whether EDA−/− mice were immunodeficient. To
determine whether EDA−/− mice demonstrated normal
white blood cell numbers and differential counts, whole
blood was assayed on an automated blood analyser.
We found no difference between EDA−/− and WT
mice (Figure 1A) in total leukocyte counts, which
was consistent with levels reported in normal mice
[33]. Differential analysis revealed similar absolute
neutrophil, lymphocyte, and mononuclear cell counts
(data not shown).
In addition to effects on T-cell development, fibro-
nectin has been reported to promote T-cell prolifer-
ation [30]. We therefore examined the proliferative
capacity of EDA−/− splenocytes compared with WT
splenocytes using 3H-thymidine incorporation follow-
ing Con A stimulation with unstimulated splenocytes
as controls. Scintillation counting revealed no differ-
ences between cell types, with both EDA−/− and WT
cells demonstrating robust proliferation in response to
Con A (Figure 1B). Basal proliferation rates in unstim-
ulated cells were also similar (Figure 1B). Together,
these observations suggest that EDA−/− immune cells
are competent with regard to homeostatic maintenance
of leukocyte populations and proliferative responses.
EDA−/− recipients acutely reject cardiac allografts
in a manner indistinguishable from WT mice
We next assessed the ability of EDA−/− mice to
acutely reject cardiac allografts in a similar fashion
to WT controls. In the heterotopic cardiac transplant
model, C57BL/6 recipients that receive no immunosup-
pression normally reject BALB/c cardiac grafts within
7–9 days in a manner consistent with dominant Th1
responses and extensive parenchymal cell death [7,8].
EDA cFN up-regulation has been reported in human
Th1 cells [34] and has been associated with infiltrating
leukocytes in acute rejection [4,22]. Thus, we asked
whether EDA−/− mice acutely reject cardiac allografts
similarly to WT controls. EDA−/− and WT recipi-
ents rejected their grafts within 8 days post-transplant.
Histological assessment of the acutely rejected allo-
grafts revealed similar degrees of mononuclear infiltra-
tion and cellular necrosis between the two genotypes
(Figure 2A). Differential counts of GICs revealed no
differences between the two genotypes with primar-
ily monocytic and lymphocytic infiltrate (Figure 2B),
suggesting equivalent inflammatory cell recruitment.
Acute allograft rejection in this model is accompa-
nied by a robust Th1 immunological response [7,8].
Thus, we performed ELISPOT analyses to enumer-
ate graft reactive IFN-γ, IL-4, and IL-17 responses
in EDA−/− and WT recipients. Comparable, domi-
nant Th1 priming was observed in splenocytes from
both groups, with relatively little Th2 or Th17 response
(Figure 2C). Collectively, the data suggest that alloim-
mune responses leading to acute rejection are replete
in EDA−/− allograft recipients.
EDA deficiency prevents fibrosis associated
with chronic rejection
Although acute rejection responses were fully apparent
in EDA−/− mice, we considered that allograft fibrosis
associated with chronic rejection might be compro-
mised in these animals given the described role for
EDA cFN in other models of fibrosis [16,35–37]. To
better ascertain the contribution of EDA cFN in car-
diac allograft fibrosis, we compared cardiac allografts
in EDA−/− and WT recipients in an established model
of chronic rejection. In this model, allograft recipients
are transiently depleted of CD4+ cells and chronic
rejection ensues as CD4+ cells begin to repopulate
the periphery [14,15,29,38,39]. We first examined the
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Figure 2. EDA−/− recipients acutely reject cardiac allografts. (A) Allograft histology in EDA−/− and WT recipients at 200× (original
magnification). H&E stains were performed on sections from allografts that were harvested at the time of rejection. Tissue sections are
representative of at least four separate cardiac allografts. (B) Differential cell counts of Wright-stained GICs. (C) Donor reactive IFN-γ,
IL-4, and IL-17 production by EDA−/− and WT recipient splenocytes in ELISPOT assays. Grafts and spleens were harvested at the time of
rejection. Points represent individual allograft recipients; lines represent mean of group.
Figure 3. EDA cFN promotes fibrotic remodelling associated with chronic cardiac allograft rejection. (A) Kinetic time course of intra-graft
EDA cFN transcript levels in WT recipients transiently depleted of CD4+ cells. Bars represent mean and SEM of three individual grafts.
(B) Representative Masson’s trichrome-stained sections of cardiac allografts harvested on day 30 post-transplant. (C) Morphometric
quantification of allograft fibrosis on day 30 post-transplant in WT and EDA−/− graft recipients. Bars illustrate mean and SEM of a
minimum of ten frames of view from at least eight independent transplants. (D) Morphometric quantification of allograft fibrosis on day
50 post-transplant in WT and EDA−/− graft recipients. Bars illustrate mean and SEM of a minimum of ten frames of view from at least six
independent hearts.
kinetics of intra-graft EDA cFN expression in this
model, which suggested an increase in intra-graft EDA
cFN transcript levels at day 30 (Figure 3A). Previous
investigations by our group revealed that day 30 post-
transplant is a critical time point in this model, with
peak levels of interstitial fibrosis and pathological car-
diac hypertrophy [14,29]. Thus, increased intra-graft
EDA cFN expression coincides with pathological man-
ifestations of chronic rejection.
Masson’s trichrome staining revealed marked differ-
ences in cardiac allograft fibrosis between genotypes
at day 30 post-transplant, with EDA−/− recipients
demonstrating significantly less fibrotic tissue deposi-
tion than WT controls (Figure 3B). Quantitative scor-
ing of these sections using morphometric analysis
of graft fibrosis revealed a striking and significant
decrease in allograft fibrosis in EDA−/− recipients
compared with WT recipients (Figure 3C). Because
WT BALB/c cardiac allografts used in these exper-
iments can produce EDA cFN, we considered that
graft origin EDA cFN might eventually compensate
for the lack in EDA−/− recipients. To this end, we
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Figure 4. Intra-graft transcripts of fibrotic markers and car-
diomyocyte hypertrophy are unchanged in EDA−/− recipients.
(A) Intra-graft expression of CTGF, collagen 1, IL-17, and IL-6
transcripts. Bars represent mean and SEM of a minimum of six
individual cardiac grafts. (B) Morphometric quantitation of car-
diomyocyte area from H&E stains of day 30 post-transplant cardiac
allografts from WT or EDA−/− recipients. Bars represent mean and
SEM of area measurements taken from ≥80 cardiac myocytes per
heart from a minimum of six hearts per group.
followed some grafts to day 50 post-transplant and
although statistically significant differences were seen
between EDA−/− and WT counterparts, the degree of
fibrosis was much more similar (Figure 3D). This indi-
cates that recipient-derived EDA cFN promotes fibrosis
associated with chronic rejection, but is ultimately not
required for the evolution of graft fibrosis, possibly
because graft-derived EDA cFN can compensate for
the absence of recipient EDA cFN.
To better understand how cardiac allografts in
EDA−/− recipients might be protected from fibrosis,
we assessed levels of factors that promote fibrosis in
this model [15,29,40]. Intra-graft transcripts of con-
nective tissue growth factor (CTGF), IL-6, and IL-17
were not different between EDA−/− and WT recipients
(Figure 4A). This may suggest that EDA cFN promotes
cardiac allograft fibrosis downstream or independently
of these cytokines.
EDA cFN is unnecessary for cardiomyocyte
hypertrophy
Chronic rejection of cardiac grafts is concomitant with
the development of pathological hypertrophy in both
this model [29] and human cardiac grafts [41]. Since
EDA cFN deficiency protected grafts from fibrotic
remodelling, we sought to determine its effects on car-
diomyocyte hypertrophy. Morphometric determination
of the cardiac myocyte area demonstrated significant
hypertrophy in allografts from both EDA−/− and WT
recipients compared with syngeneic transplanted hearts
(Figure 4B). As EDA−/− recipients display equiva-
lent mean cardiomyocyte areas, these data indicate that
recipient EDA cFN is dispensable for hypertrophic
remodelling associated with chronic rejection of car-
diac grafts.
EDA cFN is produced by splenocytes under
conditions promoting specific Th lineages
Recipient-derived GICs are a likely source of fibrosis-
promoting EDA cFN in chronic rejection of cardiac
allografts. Furthermore, as EDA−/− recipients acutely
reject WT cardiac allografts in a fashion similar to
WT recipients, differences in alloimmune responses are
unlikely to account for attenuated allograft fibrosis seen
in EDA−/− recipients. Chronic rejection in CD4+ cell
depleted recipients is associated with diminutive but
detectable levels of graft reactive Th1 and Th2 priming
[42]. Furthermore, EDA cFN has been described as a
Th1-specific molecule in human patients [34]. Hence,
we considered that specific Th1 cells may preferen-
tially produce EDA cFN and total FN. WT splenocytes
were isolated and cultured in media supplemented to
promote Th1, Th2, Th17, and Treg phenotypes. Exam-
ination of cellular transcripts revealed similar amounts
of EDA cFN production by both Th1 and Th17 cells,
with significantly greater EDA cFN expression levels
in Treg cultures (Figure 5A). When analysis of cellu-
lar transcripts was extended to total FN, significantly
increased levels of total FN were observed in Th17 and
Treg cultures, with minimal FN transcripts expressed
by Th1 and Th2 cultures (Figure 5B). Previous findings
have suggested that the ratio of EDA containing FN to
total FN production impacts the effects of FN on cellu-
lar responses [26]. Therefore, we determined the EDA
to total FN transcript ratio (Figure 5C). Interestingly,
Treg cultures had the highest transcript levels of EDA
and total FN, although the EDA/total FN ratio was
greatest in Th1 culture cells. Thus, while Treg makes
more FN than other Th lineages, Th1 cells appear to
transcribe EDA in a more concentrated fashion.
We extended our analysis of FN production by Th-
differentiated splenocyte cultures by measuring cellular
protein levels with western blotting. Consistent with
RT-PCR data (Figure 5B), Treg cultures produced
significantly higher levels of total FN than Th1 and
Th2 cultures (Figures 5D and 5E).
Increased levels of EDA cFN in serum of allograft
recipients chronically rejecting their grafts
Given that a percentage of tissue fibronectin is derived
from the circulation [43], EDA cFN in cardiac allo-
grafts may derive from this source as well as graft-
infiltrating cells. We therefore assessed levels of EDA
cFN in the serum of anti-CD4-treated WT and EDA−/−
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Figure 5. Characterization of splenocyte production of fibronectin under conditions promoting specific Th lineages. (A) Detection of total
fibronectin content in cell lysates from splenocytes cultured under conditions promoting Th1, Th2, Th17, or Treg conditions. Bands are
representative of three independent cultures; GAPDH is shown as a loading control. Results shown are representative of six independent
cultures for each condition. For a detailed description of culture conditions see the Materials and methods section. (B) Quantification
of total fibronectin protein expression as relative band density of bands represented by panel A. (C–E) Real-time PCR quantitation of
EDA cFN (C), total Fn (D), and EDA cFN/total Fn ratio (E), from splenocytes cultured under conditions promoting Th1, Th2, Th17, or Treg
differentiation. Bars represent mean and SEM of six independent cultures.
Figure 6. Serum EDA cFN levels in recipients chronically rejecting
cardiac allografts. Serum was isolated from WT or EDA−/− CD4+
cell-depleted allograft recipients 30 days following transplantation
and compared with naive, non-transplanted WT controls. Bars
represent mean and SEM of a minimum of six independent allograft
recipients or four non-transplanted controls.
cardiac allograft recipients 30 days post-transplant. WT
recipients exhibited significantly higher amounts of
EDA cFN in serum compared with non-transplanted
WT controls (Figure 6). In contrast, EDA−/− recipi-
ents of WT cardiac grafts exhibited similar levels of
EDA cFN in the serum to non-transplanted WT mice
(Figure 6). These findings suggest that circulating EDA
cFN (perhaps derived from the engrafted vasculature)
may be another important source of EDA cFN in car-
diac allografts.
Discussion
In this article, we highlight an important role for
recipient-derived EDA cFN in driving cardiac allograft
fibrosis in the setting of chronic rejection. Recent work
has described EDA cFN expression in areas of chronic
allograft vasculopathy and interstitial fibrosis in cardiac
transplants [23,25], and has suggested that EDA cFN
may be deposited by graft-infiltrating leukocytes [22].
We now extend these observations by demonstrating
that recipient-derived EDA cFN, rather than graft-
derived EDA cFN, plays an active part in promoting
the fibrotic response, as EDA-competent allografts in
EDA−/− recipients exhibited significant delay in the
onset of fibrosis. Moreover, our data suggest that Th1
cells and Treg may be the important cellular sources
of EDA cFN and total FN in this and other systems.
Fibrotic remodelling is a hallmark of chronic rejec-
tion pathology which is believed to be driven by
immune responses to donor alloantigens. However, the
interrelationship between anti-graft immune responses
and graft fibrosis is not known. Many have postulated
that these processes are linked by immune cell-derived
cytokines, namely TGF-β. However, TGF-β is known
to exert multiple graft-protective effects, making it a
tenuous therapeutic target. Furthermore, our previous
work in models of chronic cardiac allograft rejection
has revealed that TGF-β alone is insufficient to drive
allograft fibrosis and requires other co-mediators and
downstream factors for its pro-fibrotic effects [14,40].
A potential downstream mediator of TGF-β effects
could be EDA cFN, which is induced by TGF-
β in certain cell types, particularly fibroblasts [44].
We observed no significant differences in intra-graft
expression of several pro-fibrotic mediators in EDA−/−
recipients. This indicates that EDA cFN promotes
fibrosis downstream or outside of these fibrotic media-
tors. One possibility is that EDA cFN promotes fibrosis
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by preventing matrix degradation rather than promot-
ing matrix synthesis, as the balance of these pathways
determines fibrotic tissue deposition [11,45].
Our current findings reveal that recipient-derived
EDA cFN drives cardiac allograft fibrosis. We con-
sidered that recipient-derived EDA cFN could enter
the graft through multiple routes, including GICs. This
mechanism is supported by multiple immunohisto-
chemical studies that delineate a clear association of
EDA cFN expression in association with GICs [23,24].
As the majority of GICs are recipient leukocytes, EDA
cFN produced by recipient immune cells appears to
be an important immunological mediator of fibrosis in
chronic cardiac allograft rejection. Our investigations
into EDA cFN production by immune cells revealed
that both Th1 and Treg cells can produce significant
amounts of both EDA and total FN. The production
of matrix molecules by immune cells of these lineages
could provide a link between alloimmune responses
and fibrotic remodelling. However, further investiga-
tion is necessary to understand if and how Th1 and
Treg cells, generally considered of opposing functional
lineages, promote fibrosis.
It is conceivable that cellular damage by alloreactive
Th1 cells is accompanied by deposition of EDA cFN
and provides an initial fibrotic stimulus. In contrast,
Treg could simultaneously dampen immune responses
against cardiac grafts and produce FN that contributes
to fibrotic responses. One explanation for the pro-
duction of matrix molecules by Treg could be the
immune cytokine TGF-β, well known as a fibrotic
mediator. However, it should also be noted that dif-
ferences between Th17 and Treg cultures (which are
both supplemented with TGF-β) may highlight the
context-dependent signalling of TGF-β. Furthermore,
Th1 differentiation cultures, which were not supple-
mented with TGF-β, exhibited the most concentrated
production of EDA cFN, as evidenced by the EDA/total
FN ratio. This suggests that regulation of EDA cFN
production by immune cells may also occur indepen-
dently of TGF-β.
We observed increased levels of EDA cFN in the
serum of WT recipients who were chronically rejecting
their grafts. Hepatocytes secrete significant amounts
of fibronectin into the peripheral circulation, though
plasma fibronectin does not typically contain EDA
cFN [46]. Indeed, hepatocytes have been shown to
selectively retain and degrade EDA cFN when it is
produced, rather than secreting it into the circulation
[43]. Alternatively, significant evidence suggests that
EDA cFN may be produced by vascular endothelium
in response to inflammation or injury [47–49]. Hence,
the injury resulting from the anastomosis of graft aorta
and pulmonary artery to recipient aorta and inferior
vena cava in the heterotopic allograft model may
be a source of the circulating EDA cFN that we
observed. Interestingly, however, it is more likely that
the recipient vessels (rather than the graft vessels) are
the source since EDA−/− recipients did not display
an increase in serum EDA cFN. Regardless, although
the cellular origin of EDA cFN in the circulation is
unclear, it is likely that it plays a substantial role in the
development of cardiac allograft fibrosis.
Our prior work has illustrated the obligate role for
EDA cFN in normal skin wound healing [26] and lung
fibrosis following injury [16]. Although the reasons
for this have not been fully elucidated, it appears
that EDA cFN is necessary for in vivo fibroblast-to-
myofibroblast differentiation; EDA−/− mice developed
fewer α-SMA-expressing myofibroblasts in injured
areas compared with WT animals [16,26]. Moreover,
in vitro studies in both rodent and human cells show
that in the absence of EDA cFN, fibroblasts are unable
to transdifferentiate into myofibroblasts, even in the
presence of the pro-fibrotic cytokine TGF-β [16,20].
Myofibroblast transdifferentiation is a complex process
requiring both soluble factors (such as TGF-β) and
integrin signals via focal adhesion kinase [50]. Indeed,
our recent work demonstrated that α4β7 integrins,
previously thought to be restricted to leukocytes, are
expressed on the fibroblast cell surface and play an
important role in transducing EDA cFN signals, via
MAP and ERK1/2 kinases, to effect myofibroblast
transdifferentiation [51].
Together, our data describe a function for EDA cFN
as a downstream factor mediating fibrotic remodelling
responses in cardiac allografts. While current immuno-
suppressive therapeutics obviate acute rejection and
prolong organ survival, they are generally ineffective
at preventing chronic graft rejection. This highlights
the need for mechanistic evaluation to identify other
targets for potential therapeutic intervention. In addi-
tion to its potential contributions to the development of
graft fibrosis, increased EDA cFN in the serum of graft
recipients suggests that EDA cFN could be explored
as a non-invasive biomarker for the development of
chronic rejection in cardiac allografts. Furthermore,
EDA cFN and elements mediating EDA cFN signal
transduction may be therapeutic targets for limiting
fibrosis in cardiac, and potentially other solid organ,
allografts.
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